Life-changing therapies to help people build families and live better lives
At Ferring, we are committed to helping people build families and live better lives. In the United States, Ferring is a leader in reproductive medicine, uro-oncology and in specialty areas within orthopaedics, and gastroenterology, including microbiome therapeutics.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
Join us
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With over 6,000 employees in more than 50 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.
Ferring is a leader in reproductive medicine, uro-oncology and in specialty areas within orthopaedics, and gastroenterology, including microbiome therapeutics.
News
-
Ferring Announces Update to NCCN Guidelines Expanding Category 2A Recommendation for Nadofaragene Firadenovec-vncg (ADSTILADRIN®) in Patients with BCG-Unresponsive NMIBC
-Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with papillary tumors (+Ta/T1) without carcinoma in situ (CIS), an upgrade from its 2B recommendation Nadofar...
-
Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
-The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus Calmette-Guéri...
-
SUO and Ferring Pharmaceuticals Announce the SUO Non-Muscle Invasive Bladder Cancer (NMIBC) Fellows Research Grant
-Research grant empowers future leaders in clinical research to advance breakthroughs in the prevention, detection, diagnosis and treatment of NMIBC Two fellows to receive SUO NMIBC research grants ...